MedMira Inc V.MIR

Alternate Symbol(s): MMIRF

Healthcare Medical Devices

MedMira Inc. is a Canada-based developer and manufacturer of Rapid Vertical Flow (RVF) diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as human immunodeficiency virus (HIV), syphilis, hepatitis, and SARS-CoV-2, in three steps. The Company is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. Its tests are sold globally under the REVEAL, REVEALCOVID-19, Multiplo and Miriad brands. Based on its patented Rapid Vertical Flow Technology, the Company's rapid HIV test has regulatory approvals in Canada, the United States, China and the European Union. Its manufacturing facilities are located in Halifax, Nova Scotia, Canada. It provides access to its RVF Technology for researchers, developers, and biotech companies on a license basis.

TSXV:MIR - Post by User

MedMira Inc

<< Previous

Bullboard Posts

Next >>

Post by beercanon Nov 23, 2020 5:25pm

851 Views

Post# 31955056

Markus

From: Hermes Chan
To: L
Subject: Re: Antibody testing set to become a lot more relevant

Indeed, any vaccine is for prevention and always has an effective period. Vaccine is never a cure. To monitor the effectiveness of the vaccine, periodic total antibody test is a must to ensure the antibodies, both naturally occurring or vaccinated, are sufficient to protect the individual.
Antigen test, on the other hand, should be used to detect the pre-symptomatic, asymptomatic or symptomatic but I think it is most importantly to detect and distinguish between the actual case of SARS-Cov-2, Influenza and or the common cold.

Best Regards:
Hermes Chan D.Sc (h.c)
Chief Executive Officer
MedMira

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading